Pang Ying, Lei Xunming, Jiang Nianjing, et al. Application Value of Doxycycline in Children with Severe Mycoplasma Pneumoniae Pneumonia. [J]. 27(10):9-11(2021)
DOI:
Pang Ying, Lei Xunming, Jiang Nianjing, et al. Application Value of Doxycycline in Children with Severe Mycoplasma Pneumoniae Pneumonia. [J]. 27(10):9-11(2021) DOI: 10.13407/j.cnki.jpp.1672-108X.2021.10.003.
Application Value of Doxycycline in Children with Severe Mycoplasma Pneumoniae Pneumonia
Objective: To observe the efficacy of doxycycline in severe Mycoplasma pneumoniae pneumonia (SMPP) in children over 8 years old. Methods: Medical records of children over 8 years old with SMPP in our hospital from 2017 to 2019 were retrospectively analyzed. Forty-six patients with doxycycline were randomly extracted as the doxycycline group and 52 cases with azithromycin were randomly selected as the azithromycin group. Doxycycline group was given doxycycline orally (2.2 mg/kg
bid)
and azithromycin group was given azithromycin by intravenous infusion (10 mg/kg
qd)
both groups were treated for 5 to 7 d. The duration of fever
relief time of cough
disappearance time of pulmonary rales
length of stay
application rate of hormone
blood routine
C-reactive protein (CRP)
lactate dehydrogenase (LDH)
absorption of pulmonary lesions in two groups were compared. Results: Children in both groups were cured or improved. The duration of fever
relief time of cough
disappearance time of pulmonary rales
length of stay
application rate of hormone
LDH and CRP in the doxycycline group were shorter or lower than those in the azithromycin group
the absorption rate was higher than that of the azithromycin group (P<0.05). Conclusion: Oral doxycycline treatment for SMPP in children over 8 years old is safe